<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03213249</url>
  </required_header>
  <id_info>
    <org_study_id>201704134</org_study_id>
    <nct_id>NCT03213249</nct_id>
  </id_info>
  <brief_title>Bacterial Biofilms in Reconstructive Breast Prostheses Following Mastectomy</brief_title>
  <official_title>Bacterial Biofilms in Reconstructive Breast Prostheses Following Mastectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Plastic Surgery Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast implants, either cosmetic or reconstructive, are among the most common procedures&#xD;
      performed by plastic surgeons. Bacterial infections or biofilms are implicated in the&#xD;
      majority of breast implant complications including infection requiring explantation, capsular&#xD;
      contracture (CC), and/or breast-implant associated anaplastic large cell lymphoma (BIA-ALCL).&#xD;
      The research team, which has already extensively characterized bacterial pathogenesis in the&#xD;
      urinary tract and designed non-antibiotic therapeutics to reduce the incidence of&#xD;
      catheter-associated urinary tract infections (CAUTIs), and proposal will study&#xD;
      bacteria-breast implant interactions and explore further the impact of the breast microbiome.&#xD;
      The proposed research provides a greater understanding of which bacteria can colonize breast&#xD;
      implants, their source, and how effective antibiotic pocket irrigation is at eliminating&#xD;
      them, and begins to examine the mechanisms by which bacteria bind and colonize the implant&#xD;
      surface. These insights will set the groundwork for developing new therapeutic agents that&#xD;
      can disrupt the binding of certain bacteria to breast implants. Strategies that minimize&#xD;
      problems bacteria can cause, while avoiding antibiotics, will reduce bacteria-related implant&#xD;
      complications, limit antibiotic-related side effects, and reduce bacterial resistance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 25, 2017</start_date>
  <completion_date type="Actual">September 26, 2018</completion_date>
  <primary_completion_date type="Actual">September 26, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of tissue expander(s) removed due to infection</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The bulk of analyses will be to study bacterial biofilm formation on the explanted breast tissue, skin/scar, drain, acellular dermal matrix, tissue expander, and capsule.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of tissue expander(s) removed due to patient preference</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of implantation</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration the drain was in</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of development of an infection or a wound</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of capsular contracture</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Breast Implant Infection</condition>
  <condition>Mammoplasty</condition>
  <arm_group>
    <arm_group_label>Arm 1: Intraoperative pocket irrigation with NS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 gram cefazolin intravenous before surgical incision&#xD;
Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists&#xD;
Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling&#xD;
Standard of care saline pocket irrigation will receive 500 cc of normal saline alone per pocket.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 gram cefazolin intravenous before surgical incision&#xD;
Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists&#xD;
Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling&#xD;
Standard of care antibiotic pocket irrigation will receive 500 cc of normal saline plus 1 gram cefazolin, 80 mg gentamicin, and 50,000 units bacitracin</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Intraoperative pocket irrigation with normal saline</description>
    <arm_group_label>Arm 1: Intraoperative pocket irrigation with NS</arm_group_label>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
    <other_name>NS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed</description>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
    <other_name>Ancef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin biopsy</intervention_name>
    <description>Biopsies will be taken from the skin at the time of mastectomy and at the time of implant exchange.</description>
    <arm_group_label>Arm 1: Intraoperative pocket irrigation with NS</arm_group_label>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bilateral skin- or nipple-sparing mastectomies</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Arm 1: Intraoperative pocket irrigation with NS</arm_group_label>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tissue expander</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Arm 1: Intraoperative pocket irrigation with NS</arm_group_label>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Breast implant</intervention_name>
    <description>Standard of care&#xD;
Either breast implant or autologous flap</description>
    <arm_group_label>Arm 1: Intraoperative pocket irrigation with NS</arm_group_label>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous flap</intervention_name>
    <description>Standard of care&#xD;
Either breast implant or autologous flap</description>
    <arm_group_label>Arm 1: Intraoperative pocket irrigation with NS</arm_group_label>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acellular dermal matrix sling</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Arm 1: Intraoperative pocket irrigation with NS</arm_group_label>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentamicin</intervention_name>
    <description>Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed</description>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
    <other_name>Garamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bacitracin</intervention_name>
    <description>Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed</description>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Between 18 and 75 years of age, inclusive&#xD;
&#xD;
          -  Undergoing bilateral mastectomy reconstruction with tissue expanders (ipsilateral&#xD;
             therapeutic/contralateral prophylactic) planned to be exchanged for breast implants&#xD;
&#xD;
          -  Able to understand and willing to sign an IRB-approved written informed consent&#xD;
             document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terence M Myckatyn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 22, 2017</study_first_submitted>
  <study_first_submitted_qc>July 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>February 6, 2019</last_update_submitted>
  <last_update_submitted_qc>February 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Bacitracin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

